First: too many Medtech innovations fail to reach and benefit patients.

This is partly due to complex development and regulatory cycles. Additionally, for many innovations the presumed impact on patients, providers and insurers is not validated early enough.

Care IQ uses its own blend for Health Technology Assessments (HTAs) and Design Thinking to overcome these challenges: by working closely with both innovators and end-users, we ensure that the solutions not only meet the technical specifications but also align with practical, day-to-day healthcare needs. Our collaborative approach fosters an environment where feedback is continuously integrated, refining the innovation process at every stage. This iterative development, guided by the motto “fail fast, to scale fast,” paradoxically ensures that by the time these innovations reach the market, they are robust, reliable, and ready to make a meaningful impact.

Moreover, … 

… our emphasis on early validation of assumptions and market strategies minimises the risk of costly missteps. By engaging with our extensive network early on, companies can pivot quickly if necessary, ensuring that their innovations remain relevant and competitive. This proactive strategy not only saves time and resources but also accelerates the journey from concept to commercialisation.

At Care IQ ultimately, our goal is to bridge the gap between groundbreaking medical technology and the patients who stand to benefit most. By doing so, we contribute to a care landscape that is more efficient, patient-centered, and poised to tackle the challenges of tomorrow with innovative solutions that truly make a difference.